Abstract
The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non-squamous cell head and neck cancers (NSCC-HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti-androgen agents and drugs administered orally, more targetable AR-driven NSCC-HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.
Keywords:
abiraterone; androgen receptor; enzalutamide; head and neck; immunohistochemistry; non-squamous cell carcinoma; salivary gland carcinoma.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Adenocarcinoma / diagnosis*
-
Adenocarcinoma / drug therapy*
-
Administration, Oral
-
Androgen Antagonists / administration & dosage*
-
Androstenes / administration & dosage
-
Anilides / administration & dosage
-
Antineoplastic Agents / administration & dosage*
-
Benzamides
-
Biomarkers, Tumor / analysis*
-
Carcinoma, Adenoid Cystic / diagnosis*
-
Carcinoma, Adenoid Cystic / drug therapy*
-
Carcinoma, Mucoepidermoid / diagnosis*
-
Carcinoma, Mucoepidermoid / drug therapy*
-
Female
-
Humans
-
Male
-
Molecular Targeted Therapy*
-
Nitriles / administration & dosage
-
Phenylthiohydantoin / administration & dosage
-
Phenylthiohydantoin / analogs & derivatives
-
Receptors, Androgen / analysis*
-
Salivary Ducts*
-
Salivary Gland Neoplasms / diagnosis*
-
Salivary Gland Neoplasms / drug therapy*
-
Tosyl Compounds / administration & dosage
Substances
-
Androgen Antagonists
-
Androstenes
-
Anilides
-
Antineoplastic Agents
-
Benzamides
-
Biomarkers, Tumor
-
Nitriles
-
Receptors, Androgen
-
Tosyl Compounds
-
Phenylthiohydantoin
-
enzalutamide
-
bicalutamide
-
abiraterone